Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.42 |
| ▸ | OPRM1 known ✓ | P35372 | 8/20 | 0.39 |
| ▸ | OPRD1 known ✓ | P41143 | 2/20 | 0.39 |
| ▸ | OPRK1 known ✓ | P41145 | 2/20 | 0.39 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.37 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.37 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20447769 | 1.00 | ALOX15 (0.42) | ALOX15MGAMGAASIMGAM2 | |
| SCHEMBL372547 | 0.98 | — | — | |
| SCHEMBL22441532 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL1279085 | 0.91 | ALOX15 (0.39) | ALOX15MGAMGAASIMGAM2 | |
| Hydrochloric Acid SCHEMBL1279280 | 0.91 | SMN1; SMN2 (0.42) | ALOX15MGAMGAASIMGAM2 | |
| Hydrochloric Acid SCHEMBL1812212 | 0.90 | SMN1; SMN2 (0.38) | ALOX15MGAMGAASIMGAM2 | |
| Hydrochloric Acid SCHEMBL242120 | 0.90 | SMN1; SMN2 (0.38) | ALOX15MGAMGAASIMGAM2 | |
| SCHEMBL571438 | 0.89 | SMN1; SMN2 (0.44) | ALOX15MGAMGAASIMGAM2 | |
| SCHEMBL2507803 | 0.89 | ALOX15 (0.41) | ALOX15MGAMGAASIMGAM2 | |
| SCHEMBL16111684 | 0.88 | ALOX15 (0.37) | ALOX15MGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 443 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117903078-A | Amide derivative containing 3, 4-dichloro isothiazole, preparation method and application thereof | 南开大学 | 2024-04-19 | — | — | CN | claimed |
| CN-109010161-B | Preparation method of tuber melanosporum extract and application of tuber melanosporum extract in hair dyeing composition | GUANGDONG RUIBANG DAILY CHEMICAL Co.,Ltd. (CN) | 2021-06-22 | — | — | CN | claimed |
| EP-3941459-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12516037-B2 | Substituted thiophenecarboxamides and analogues as antibacterials agents | BAYER AKTIENGESELLSCHAFT (DE) | 2026-01-06 | — | — | US | disclosed |
| US-12509437-B2 | Substituted thiophene carboxamides and derivatives thereof as microbicides | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-30 | — | — | US | disclosed |
| US-20250320225-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-12404241-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255869-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA | KURA ONCOLOGY INC (US) | 2025-08-14 | — | — | US | disclosed |
| US-12384790-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-24 | — | — | US | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1338600-A1 | Fused 1,2,4-Thiadiazine derivatives, their preparation and use | NOVO NORDISK A/S (DK) | 2003-08-27 | — | — | EP | disclosed |
| EP-1140945-B1 | FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 2003-06-04 | — | — | EP | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-20020086861-A1 | Fused 1,2,4- thiadiazine derivatives, their preparation and use | HANSEN JOHN BONDO (DK) | 2002-07-04 | — | — | US | disclosed |
| US-6329367-B1 | NERVOUS SYSTEM DISORDERS AND CARDIOVASCULAR DISORDERS | NOVO NORDISK A/S (DK) | 2001-12-11 | — | — | US | disclosed |
| EP-1140945-A1 | FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037474-A1 | FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-06-29 | — | — | WO | disclosed |
| US-4351842-A | N-Cyclopropylisoindolines | GLAXO LABORATORIES LIMITED (GB) | 1982-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | LPAR1, LPAR2, LPAR3 | GAA 3161/4885OPRM1 754/4885OPRD1 1480/4885 |
| US-12509437-B2 | Substituted thiophene carboxamides and derivatives thereof as microbicides | CBR1, CBR3, CCR2 | GAA 3334/4885OPRM1 409/4885OPRD1 908/4885 |
| US-20250320225-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | MLLT1, MEN1, MLLT3 | GAA 4266/4885OPRM1 4825/4885OPRD1 4875/4885 |
| US-20250255869-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA | MEN1, DIAPH1, EWSR1 | GAA 2712/4885OPRM1 4879/4885OPRD1 4884/4885 |
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | GAA 3253/4885OPRM1 4698/4885OPRD1 4336/4885 |
| US-20020086861-A1 | Fused 1,2,4- thiadiazine derivatives, their preparation and use | CYP4F3, TBXAS1, NR3C2 | GAA 4195/4885OPRM1 2475/4885OPRD1 951/4885 |
| US-12404241-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | AR, NR5A2, ESRRA | GAA 4544/4885OPRM1 77/4885OPRD1 101/4885 |
| US-12384790-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | GAA 2063/4885OPRM1 4618/4885OPRD1 4128/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | GAA 4278/4885OPRM1 727/4885OPRD1 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.